China-based Zhejiang Fonow Medicine Co., Ltd. (formerly known as: Zhejiang Rishengchang Pharmaceutical Co., Ltd.) has announced the official market launch of its fluocinolone acetonide, hydroquinone, and tretinoin cream in China for the treatment of melasma. This marks a significant advancement in the treatment landscape for this common pigmentation disorder.
Innovative Triple Mechanism
The drug stands out as the first triple cream preparation approved for melasma in China, featuring a triple mechanism of action: “inhibiting melanin production + accelerating metabolism + anti-inflammation.” This comprehensive approach addresses multiple aspects of melasma pathology, potentially offering improved efficacy and patient outcomes compared to conventional treatments.-Fineline Info & Tech
Leave a Reply